4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -102.69% |
| Mar 31, 2026 | 448.96% |
| Dec 31, 2025 | -1,820.00% |
| Sep 30, 2025 | -100.43% |
| Jun 30, 2025 | -15.64% |
| Mar 31, 2025 | 193.15% |
| Dec 31, 2024 | -20.98% |
| Sep 30, 2024 | 29.70% |
| Jun 30, 2024 | 30.42% |
| Mar 31, 2024 | 29.33% |
| Dec 31, 2023 | 35.56% |
| Sep 30, 2023 | -49.69% |
| Jun 30, 2023 | -20.45% |
| Mar 31, 2023 | -7.41% |
| Dec 31, 2022 | -44.35% |
| Sep 30, 2022 | -4.94% |
| Jun 30, 2022 | -67.78% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | 93.40% |
| Sep 30, 2021 | 257.53% |